Loading...
•
Sep 30, 2024
AbCellera Q3 2024 Earnings Report
Reported financial results for the third quarter of 2024, highlighting progress in internal pipeline advancement and infrastructure investments.
Key Takeaways
AbCellera reported total revenue of $6.5 million, a net loss of $51.1 million, and continued investment in research and development. The company also expanded its collaboration with Eli Lilly and Company and maintained a strong liquidity position with over $875 million available.
Expanded collaboration with Eli Lilly and Company.
Reported 95 partner-initiated program starts with downstreams.
Maintained 14 molecules advanced to the clinic.
Completed consolidation into new headquarters in Vancouver, Canada.
Revenue by Segment
Forward Guidance
This press release contains forward-looking statements regarding the company's ability to develop, commercialize and achieve market acceptance of its current and planned products and services, its research and development efforts, and other matters regarding its business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...